자궁내막증 치료 시장 규모, 점유율, 동향 분석 보고서 : 치료 유형별, 약제 클래스별, 투여 경로별, 유통 채널별, 지역별, 부문 예측(2025-2030년)
Endometriosis Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
상품코드
:
1654447
리서치사
:
Grand View Research, Inc.
발행일
:
2025년 01월
페이지 정보
:
영문 150 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
자궁내막증 치료 시장의 성장과 동향
Grand View Research, Inc의 최신 보고서에 따르면 세계의 자궁내막증 치료제 시장 규모는 2025-2030년 동안 12.25%의 연평균 복합 성장률(CAGR)을 보이고, 2030년까지 35억 2,000만 달러에 달할 것으로 예상됩니다.
이러한 시장 성장의 배경에는 후기 단계의 강력한 제품 파이프라인의 존재, 전 세계에서 급증하는 환자 수, 질병에 대한 인식을 높이기 위해 정부와 주요 기업이 국내외에서 진행하고 있는 여러 노력들이 있습니다.
우주에서 새로운 치료 옵션의 연구개발의 성장은 향후 수년간 시장 성장에 유리한 기회를 제공할 것으로 예상됩니다. Myovant/Pfizer의 Relugolix 복합제, ObsEva의 Yselty(린자고릭스), Ferring Pharmaceuticals/Novartis의 Quinagolide의 출시는 이 분야에서 주목할 만한 약물의 출시 중 하나이며, 시장 성장을 가속할 것으로 예상됩니다.
자궁내막증 치료에 대한 수요 증가는 질병 부담 증가와 진단 지연으로 인한 질병 상태의 악화에 기인하며, WHO에 따르면 2021년 3월에는 여성 생식 인구의 약 10%가 이 질환을 앓고 있다고 합니다. '자궁내막증 진단 지연이 의료자원 이용과 비용에 미치는 영향'이라는 논문에 따르면 첫 증상 발생 후 3년 이상 진단이 늦어지면 증상 발현 후 조기에 진단받은 환자에 비해 증상 부담이 증가하고 의료비용이 50% 증가한다고 합니다.
WHO, 각국 정부 및 민간단체는 자궁내막증과 그 치료에 대한 홍보 및 인식 개선에 전략적으로 노력하고 있으며, 이는 시장 성장을 지원하고 있습니다. 예를 들어 2022년 3월 미국 자궁내막증 재단(Endometriosis Foundation of America)은 환자와 의사가 참여하는 가상 프로그램을 4번의 주말에 걸쳐 개최하여 자궁내막증 전사를 연결하고 이 질병에 대한 경험을 공유하는 데 기여했습니다. 또한 2022년 3월 영국 자궁내막증 협회도 '자궁내막증 행동의 달'을 맞아 8가지 실천 계획을 수립했습니다.
또한 주요 기업은 인수합병, 제휴, 재정 투자, 지역적 확장 등 전략적 구상을 취해 자궁내막증 치료제 시장을 자극하고 있습니다. 예를 들어 2021년 11월 Organon and Co.는 Forendo Pharma의 인수를 발표하여 Forendo의 임상 2상 후보물질인 OR-6219와 같은 자궁내막증 신약 개발을 지원할 예정입니다.
자궁내막증 치료 시장 보고서 하이라이트
- 치료 유형별로는 의사의 처방률이 높은 호르몬 요법이 2024년 시장에서 가장 큰 점유율을 차지했습니다.
- 성선자극호르몬 방출 호르몬(GnRH) 부문은 GnRH 작용제 및 GnRH 길항제의 높은 효능과 시장에서 이러한 제품의 가용성 증가로 인해 2024년 약품군별 부문을 지배했습니다.
- 2024년 투여 경로별 점유율은 경구제가 48.46%로 시장을 독점했습니다. 경구 투여는 이 부문 대부분의 제품에서 가장 보편적이고 편리한 투여 경로입니다.
- 2024년 유통 채널별로는 소매 약국 부문이 시장을 독점했습니다. 또한 병원 약국은 완만한 성장이 예상됩니다.
- 북미가 2024년 세계 시장을 석권했는데, 이는 질병 이환율 상승과 증상 치료에 대한 국민과 의료 전문가들의 높은 인식에 기인합니다.
목차
제1장 조사 방법과 범위
제2장 개요
제3장 시장의 변수와 동향
- 시장 계통 전망
- 시장 동향과 전망
- 시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
- 비즈니스 환경 분석
- Porter's Five Forces 분석
- PESTEL 분석
- 파이프라인 분석(단계 3)
제4장 자궁내막증 치료 시장 - 치료 유형별 부문 분석, 2018-2030년
- 자궁내막증 치료 시장 : 치료 유형의 변동 분석
- 치료 유형별
제5장 자궁내막증 치료 시장 - 약제 클래스별 부문 분석, 2018-2030년
- 자궁내막증 치료 시장 : 약제 클래스의 변동 분석
- 약제 클래스별
- NSAID
- 경구 피임약
- 고나도트로핀 방출 호르몬
- 기타
제6장 자궁내막증 치료 시장 - 투여 경로별 부문 분석, 2018-2030년
- 자궁내막증 치료 시장 : 투여 경로의 변동 분석
- 투여 경로별
제7장 자궁내막증 치료 시장 - 유통 채널별 부문 분석, 2018-2030년
- 자궁내막증 치료 시장 : 유통 채널의 변동 분석
- 유통 채널별
제8장 자궁내막증 치료 시장 : 유형, 약제 클래스, 투여 경로, 유통 채널에 의한 지역별, 추정·동향 분석
- 자궁내막증 치료 시장 : 지역별 전망
- 북미
- 유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트
제9장 경쟁 구도
- 참여 기업
- Participants'Overviews
- 기업의 시장 현황 분석
- 기업 개요
- Bayer AG
- Pfizer, Inc.
- AbbVie, Inc
- AstraZeneca
- ObsEva SA
- Teva Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- ELI LILLY AND COMPANY
- Astellas Pharma, Inc.
- 전략 지도제작
- 신제품의 발매
- 취득
- 협업
- 파트너십
- 기타(임상 검사, 캠페인, 법률, 가격결정)
제10장 결론
KSA
영문 목차
Endometriosis Treatment Market Growth & Trends:
The global endometriosis treatment market size is expected to reach USD 3.52 billion by 2030, registering a CAGR of 12.25% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market growth is attributed to the presence of a late-stage robust product pipeline, the global upsurge in cases, and several initiatives undertaken by the government and key players at national and international levels to raise disease awareness.
The growing research and development for new treatment options in space is expected to offer a lucrative opportunity for market growth in the coming years. The launch of Myovant / Pfizer's Relugolix combination tablet, ObsEva's Yselty (linzagolix), and Ferring Pharmaceuticals / Novartis' Quinagolide are among prominent drug launches in this space that are anticipated to fuel the market growth.
Rising demand for endometriosis treatment is attributed to increasing disease burden and delay in diagnosis, worsening the disease condition. In March 2021, as per WHO, approximately 10% of female reproductive population is affected by the disease worldwide. According to the article, "Impact of Endometriosis Diagnostic Delays on Healthcare Resource Utilization and Costs", a delay of three or more years in diagnosis from developing first symptom leads to increase in symptom burden and increase in healthcare cost by 50% compared with patients who were diagnosed earlier after symptom onset.
WHO, national governments, and private organizations are strategically involved in spreading awareness and educating people about endometriosis and its treatment, thereby supporting market growth. For instance, in March 2022, the Endometriosis Foundation of America hosted four weekends of the virtual program featuring patients and physicians, helping to connect endometriosis warriors and share their experiences with the disease. Moreover, in March 2022, Endometriosis U.K. also launched an eight-point action plan during the 'Endometriosis Action Month'.
Furthermore, key players are undertaking strategic initiatives such as mergers and acquisitions, collaborations, financial investments, and geographical expansion fueling the endometriosis treatment market. For instance, in November 2021, Organon and Co. announced to acquire Forendo Pharma, which will support Forendo's development of novel drugs in endometriosis like OR-6219, a phase 2 clinical candidate.
Endometriosis Treatment Market Report Highlights:
- By treatment type, the hormone therapy segment accounted for the largest share of the market in 2024 due to the high prescription rate of these drugs by physicians
- Gonadotropin-releasing hormone (GnRH) segment dominated the drug class segment in 2024 due to the high efficacy of GnRH agonists and GnRH antagonists and the increased availability of these products in the market
- In 2024, oral segment dominated the market with a 48.46% share by route of administration. It is the most common & convenient route of delivery for the majority of products in this space
- In 2024, retail pharmacy segment dominated the market by distribution channel. Moreover, hospital pharmacy is expected to demonstrate moderate growth
- North America dominated the global market in 2024 owing to increased disease incidence and high awareness among people and healthcare professionals about the condition therapies
Table of Content
Chapter 1 Methodology and Scope
- 1.1 Market Segmentation
- 1.2 Market Definitions
- 1.2.1 Estimates And Forecast Timeline
- 1.3 Objectives
- 1.3.1 Objective - 1
- 1.3.2 Objective - 2
- 1.3.3 Objective - 3
- 1.4 Research Methodology
- 1.5 Information Procurement
- 1.5.1 Purchased Database
- 1.5.2 Gvr's Internal Database
- 1.5.3 Secondary Sources
- 1.5.4 Primary Research
- 1.5.5 Details Of Primary Research
- 1.6 Information or Data Analysis
- 1.6.1 Data Analysis Models
- 1.7 Market Formulation & Validation
- 1.8 Model Details
- 1.8.1 Commodity Flow Analysis
- 1.8.1.1 Approach 1: Commodity Flow Approach
- 1.8.1.2 Approach 2: Country wise market estimation using bottom-up approach
- 1.9 List of Secondary Sources
- 1.10 List of Abbreviations
Chapter 2 Executive Summary
- 2.1 Market Snapshot
- 2.2 Treatment Type and Drug Class Segment Snapshot
- 2.3 Route of Administration and Distribution Channel Segment Snapshots
- 2.4 Competitive Landscape Snapshot
Chapter 3 Market Variables and Trends
- 3.1 Market Lineage Outlook
- 3.1.1 Parent Market Outlook
- 3.1.2 Related/Ancillary Market Outlook
- 3.2 Market Trends & Outlook
- 3.3 Market Dynamics
- 3.3.1 Market Driver Analysis
- 3.3.1.1 Rising disease burden
- 3.3.1.2 Growing awareness toward the disease
- 3.3.1.3 Increasing funding for research and development
- 3.3.2 Market Restraint Analysis
- 3.3.2.1 Availability of over the counter and generic drugs
- 3.4 Business Environment Analysis
- 3.4.1 PORTER'S Five Forces Analysis
- 3.4.2 PESTEL Analysis
- 3.5 Pipeline Analysis (Phase 3)
Chapter 4 Endometriosis Treatment Market- Segment Analysis, by Treatment Type, 2018 - 2030 (USD Million)
- 4.1 Endometriosis Treatment Market: Treatment Type Movement Analysis
- 4.2 Endometriosis Treatment Market Estimates & Forecast, By Treatment Type (USD Million)
- 4.2.1 Pain Medication
- 4.2.2 Hormone Therapy
Chapter 5 Endometriosis Treatment Market- Segment Analysis, by Drug Class, 2018 - 2030 (USD Million)
- 5.1 Endometriosis Treatment Market: Drug Class Movement Analysis
- 5.2 Endometriosis Treatment Market Estimates & Forecast, By Drug Class (USD Million)
- 5.2.1 Nsaids
- 5.2.2 Oral Contraceptives
- 5.2.3 Gonadotropin-Releasing Hormone
- 5.2.4 Others
Chapter 6 Endometriosis Treatment Market- Segment Analysis, by Route of Administration, 2018 - 2030 (USD Million)
- 6.1 Endometriosis Treatment Market: Route of Administration Movement Analysis
- 6.2 Endometriosis Treatment Market Estimates & Forecast, By Route of Administration (USD Million)
- 6.2.1 Oral
- 6.2.2 Injectable
- 6.2.3 Others
Chapter 7 Endometriosis Treatment Market- Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)
- 7.1 Endometriosis Treatment Market: Distribution Channel Movement Analysis
- 7.2 Endometriosis Treatment Market Estimates & Forecast, By Distribution Channel (USD Million)
- 7.2.1 Hospital Pharmacies
- 7.2.2 Retail Pharmacies
- 7.2.3 Others
Chapter 8 Endometriosis Treatment Market: Regional Estimates and Trend Analysis by Type, Drug Class, Route of Administration, and Distribution Channel
- 8.1 Endometriosis Treatment Market: Regional Outlook
- 8.2 North America
- 8.2.1 North America Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.2.2 U.S.
- 8.2.2.1 Key Country Dynamics
- 8.2.2.2 U.S. Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.2.3 Competitive/Market Scenario
- 8.2.2.4 Regulatory Framework
- 8.2.2.5 Reimbursement Scenario
- 8.2.3 Canada
- 8.2.3.1 Key Country Dynamics
- 8.2.3.2 Canada Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.3.3 Competitive/Market Scenario
- 8.2.3.4 Regulatory Framework
- 8.2.3.5 Reimbursement Scenario
- 8.2.4 Mexico
- 8.2.4.1 Key Country Dynamics
- 8.2.4.2 Mexico Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.4.3 Competitive/Market Scenario
- 8.2.4.4 Regulatory Framework
- 8.2.4.5 Reimbursement Scenario
- 8.3 Europe
- 8.3.1 Europe Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.3.2 UK
- 8.3.2.1 Key Country Dynamics
- 8.3.2.2 UK Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.2.3 Competitive/Market Scenario
- 8.3.2.4 Regulatory Framework
- 8.3.2.5 Reimbursement Scenario
- 8.3.3 Germany
- 8.3.3.1 Key Country Dynamics
- 8.3.3.2 Germany Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.3.3 Competitive/Market Scenario
- 8.3.3.4 Regulatory Framework
- 8.3.3.5 Reimbursement Scenario
- 8.3.4 France
- 8.3.4.1 Key Country Dynamics
- 8.3.4.2 France Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.4.3 Competitive/Market Scenario
- 8.3.4.4 Regulatory Framework
- 8.3.4.5 Reimbursement Scenario
- 8.3.5 Italy
- 8.3.5.1 Key Country Dynamics
- 8.3.5.2 Italy Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.5.3 Competitive/Market Scenario
- 8.3.5.4 Regulatory Framework
- 8.3.5.5 Reimbursement Scenario
- 8.3.6 Spain
- 8.3.6.1 Key Country Dynamics
- 8.3.6.2 Spain Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.6.3 Competitive/Market Scenario
- 8.3.6.4 Regulatory Framework
- 8.3.6.5 Reimbursement Scenario
- 8.3.7 Denmark
- 8.3.7.1 Key Country Dynamics
- 8.3.7.2 Denmark Influenza Vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.3.7.3 Competitive/Market Scenario
- 8.3.7.4 Regulatory Framework
- 8.3.7.5 Reimbursement Scenario
- 8.3.8 Sweden
- 8.3.8.1 Key Country Dynamics
- 8.3.8.2 Sweden Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.8.3 Competitive/Market Scenario
- 8.3.8.4 Regulatory Framework
- 8.3.8.5 Reimbursement Scenario
- 8.3.9 Norway
- 8.3.9.1 Key Country Dynamics
- 8.3.9.2 Norway Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.9.3 Competitive/Market Scenario
- 8.3.9.4 Regulatory Framework
- 8.3.9.5 Reimbursement Scenario
- 8.3.10 Rest Of Europe Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.4 Asia Pacific
- 8.4.1 Asia Pacific Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.4.2 Japan
- 8.4.2.1 Key Country Dynamics
- 8.4.2.2 Japan Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.4.2.3 Competitive/Market Scenario
- 8.4.2.4 Regulatory Framework
- 8.4.2.5 Reimbursement Scenario
- 8.4.3 China
- 8.4.3.1 Key Country Dynamics
- 8.4.3.2 China Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.4.3.3 Competitive/Market Scenario
- 8.4.3.4 Regulatory Framework
- 8.4.3.5 Reimbursement Scenario
- 8.4.4 India
- 8.4.4.1 Key Country Dynamics
- 8.4.4.2 India Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.4.4.3 Competitive/Market Scenario
- 8.4.4.4 Regulatory Framework
- 8.4.4.5 Reimbursement Scenario
- 8.4.5 Australia
- 8.4.5.1 Key Country Dynamics
- 8.4.5.2 Australia Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.4.5.3 Competitive/Market Scenario
- 8.4.5.4 Regulatory Framework
- 8.4.5.5 Reimbursement Scenario
- 8.4.6 Thailand
- 8.4.6.1 Key Country Dynamics
- 8.4.6.2 Thailand Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.4.6.3 Competitive/Market Scenario
- 8.4.6.4 Regulatory Framework
- 8.4.6.5 Reimbursement Scenario
- 8.4.7 South Korea
- 8.4.7.1 Key Country Dynamics
- 8.4.7.2 South Korea Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.4.7.3 Competitive/Market Scenario
- 8.4.7.4 Regulatory Framework
- 8.4.7.5 Reimbursement Scenario
- 8.4.8 Rest Of Asia Pacific Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5 Latin America
- 8.5.1 Latin America Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.2 Brazil
- 8.5.2.1 Key Country Dynamics
- 8.5.2.2 Brazil Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.2.3 Competitive/Market Scenario
- 8.5.2.4 Regulatory Framework
- 8.5.2.5 Reimbursement Scenario
- 8.5.3 Argentina
- 8.5.3.1 Key Country Dynamics
- 8.5.3.2 Argentina Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.3.3 Competitive/Market Scenario
- 8.5.3.4 Regulatory Framework
- 8.5.3.5 Reimbursement Scenario
- 8.5.4 Rest Of Latin America Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.6 Middle East & Africa (MEA)
- 8.6.1 Mea Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.6.2 South Africa
- 8.6.2.1 Key Country Dynamics
- 8.6.2.2 South Africa Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.2.3 Competitive/Market Scenario
- 8.6.2.4 Regulatory Framework
- 8.6.2.5 Reimbursement Scenario
- 8.6.3 Saudi Arabia
- 8.6.3.1 Key Country Dynamics
- 8.6.3.2 Saudi Arabia Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.3.3 Competitive/Market Scenario
- 8.6.3.4 Regulatory Framework
- 8.6.3.5 Reimbursement Scenario
- 8.6.4 UAE
- 8.6.4.1 Key Country Dynamics
- 8.6.4.2 UAE Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.4.3 Competitive/Market Scenario
- 8.6.4.4 Regulatory Framework
- 8.6.4.5 Reimbursement Scenario
- 8.6.5 Kuwait
- 8.6.5.1 Key Country Dynamics
- 8.6.5.2 Kuwait Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.5.3 Competitive/Market Scenario
- 8.6.5.4 Regulatory Framework
- 8.6.5.5 Reimbursement Scenario
- 8.6.6. Rest of MEA Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 9 Competitive Landscape
- 9.1 Participant Categorization
- 9.2 Participants' Overviews
- 9.3 Financial Performance
- 9.4 Product Benchmarking
- 9.5 Company Market Position Analysis
- 9.6 Company Profiles
- 9.6.1 Bayer AG
- 9.6.1.1 Company Overview
- 9.6.1.2 Financial Performance
- 9.6.1.3 Product Benchmarking
- 9.6.1.4 Strategic Initiatives
- 9.6.2 Pfizer, Inc.
- 9.6.2.1 Company Overview
- 9.6.2.2 Financial Performance
- 9.6.2.3 Product Benchmarking
- 9.6.2.4 Strategic Initiatives
- 9.6.3 AbbVie, Inc
- 9.6.3.1 Company Overview
- 9.6.3.2 Financial Performance
- 9.6.3.3 Product Benchmarking
- 9.6.3.4 Strategic Initiatives
- 9.6.4 AstraZeneca
- 9.6.4.1 Company Overview
- 9.6.4.2 Financial Performance
- 9.6.4.3 Product Benchmarking
- 9.6.4.4 Strategic Initiatives
- 9.6.5 ObsEva SA
- 9.6.5.1 Company Overview
- 9.6.5.2 Financial Performance
- 9.6.5.3 Product Benchmarking
- 9.6.5.4 Strategic Initiatives
- 9.6.6 Teva Pharmaceutical Industries Ltd.
- 9.6.6.1 Company Overview
- 9.6.6.2 Financial Performance
- 9.6.6.3 Product Benchmarking
- 9.6.6.4 Strategic Initiatives
- 9.6.7 Teva Pharmaceutical Industries Ltd.
- 9.6.7.1 Company Overview
- 9.6.7.2 Financial performance
- 9.6.7.3 Product Benchmarking
- 9.6.7.4 Strategic Initiatives
- 9.6.8 ELI LILLY AND COMPANY
- 9.6.8.1 Company Overview
- 9.6.8.2 Financial performance
- 9.6.8.3 Product Benchmarking
- 9.6.8.4 Strategic Initiatives
- 9.6.9 Astellas Pharma, Inc.
- 9.6.9.1 Company Overview
- 9.6.9.2 Financial performance
- 9.6.9.3 Product Benchmarking
- 9.6.9.4 Strategic Initiatives
- 9.7 Strategy Mapping
- 9.7.1 New Product Launches
- 9.7.2 Acquisition
- 9.7.3 Collaborations
- 9.7.4 Partnerships
- 9.7.5 Others (Clinical Trials, Campaign, Legal, And Pricing)
Chapter 10 Conclusion
관련자료
